US-based Yingli Pharma, a company dedicated to developing drugs for both the China and US markets, has announced that it has received clinical trial approval from China’s National Medical Products Administration (NMPA) for its investigational drug YL-17231 in the treatment of advanced malignant solid tumors. This follows the previous approval for trials in the US, marking a significant step forward for the company’s pan-KRAS inhibitor.
YL-17231: A Pioneering Pan-KRAS Inhibitor
YL-17231 is an orally administered small molecule inhibitor that targets multiple KRAS mutations by binding to the KRAS switch II pocket. It is recognized as the world’s first pan KRAS mutant inhibitor to enter clinical development. KRAS is one of the most frequently mutated genes in cancer, with KRAS-driven mutations affecting approximately 25% of cancer patients. The most common mutations, G12C, G12D, and G12V, occur across a variety of tumor types.
Yingli Pharma’s Pipeline and Breakthrough Therapies
Founded in 2011 and based in Zhangjiang, Shanghai, Yingli Pharma boasts a pipeline that includes linperlisib, a Category 1 anti-tumor drug with breakthrough therapy designation (BTD) from the Center for Drug Evaluation (CDE). Linperlisib is indicated for the treatment of recurrent/refractory (R/R) follicular lymphoma (FL) and obtained marketing approval from the NMPA in November of the previous year.-Fineline Info & Tech
